Sam Brusco, Associate Editor05.15.24
Atraverse Medical has earned U.S. Food and Drug Administration (FDA) clearance for its HOTWIRE radiofrequency (RF) guidewire, which allows zero exchange left-heart access while also acting as a rail for catheter-based therapy systems.
Invented by Atraverse co-founders Dr. Steven Mickelsen and Eric Sauter, HOTWIRE features universal sheath compatibility and optimized RF technology. Dr. Mickelsen is also a cardiac electrophysiology physician at La Jolla, Calif.’s Scripps Hospital.
"The FDA clearance of the HOTWIRE underscores our dedication to medical innovation and our commitment to improving the standard of care for procedures requiring transseptal access including endocardial ablation, left atrial appendage closure, and mitral valve repair," he told the press.
Following the FDA clearance, Atraverse said it will present initial clinical experiences and conduct HOTWIRE demonstrations at the upcoming Heart Rhythm Society meeting in Boston, Mass. Dr. Mickelsen will also introduce HOTWIRE during the Stanford Biodesign New Arrhythmia Technologies Retreat.
The San Diego-based company has also secured $12.5 million of total seed investment after a recent oversubscription of its seed round. The financing, according to Atraverse, includes investment from world-class physicians, reputable venture investors, and successful medical technology entrepreneurs.
The funding will reportedly be used for the company’s R&D and early commercialization initiatives.
We are thrilled to have achieved FDA clearance in less than two years since founding the company, and the completion of our seed round positions Atraverse Medical for continued success in transforming the landscape of left-heart access," said Atraverse co-founder, president, and CEO John Slump.
Invented by Atraverse co-founders Dr. Steven Mickelsen and Eric Sauter, HOTWIRE features universal sheath compatibility and optimized RF technology. Dr. Mickelsen is also a cardiac electrophysiology physician at La Jolla, Calif.’s Scripps Hospital.
"The FDA clearance of the HOTWIRE underscores our dedication to medical innovation and our commitment to improving the standard of care for procedures requiring transseptal access including endocardial ablation, left atrial appendage closure, and mitral valve repair," he told the press.
Following the FDA clearance, Atraverse said it will present initial clinical experiences and conduct HOTWIRE demonstrations at the upcoming Heart Rhythm Society meeting in Boston, Mass. Dr. Mickelsen will also introduce HOTWIRE during the Stanford Biodesign New Arrhythmia Technologies Retreat.
The San Diego-based company has also secured $12.5 million of total seed investment after a recent oversubscription of its seed round. The financing, according to Atraverse, includes investment from world-class physicians, reputable venture investors, and successful medical technology entrepreneurs.
The funding will reportedly be used for the company’s R&D and early commercialization initiatives.
We are thrilled to have achieved FDA clearance in less than two years since founding the company, and the completion of our seed round positions Atraverse Medical for continued success in transforming the landscape of left-heart access," said Atraverse co-founder, president, and CEO John Slump.